MINNEAPOLIS — Boston Scientific Corp. said Friday it has agreed to pay $195 million to settle around 4,000 claims involving heart defibrillators and pacemakers made by Guidant Corp., which it acquired ...

Guidant, a subsidiary of Natick, Mass.-based Boston Scientific, has agreed to pay $9.25 million to settle False Claims Act charges over the company’s alleged cost inflation for pacemakers and ...

The FDA has issued a safety alert for several models of Boston Scientific’s Endotak Reliance defibrillation leads after identifying a serious defect linked to 16 deaths and 386 injuries. The leads, ...

Boston Scientific Corp., one of the nation's biggest medical device firms, said Thursday that it has won clearance from U.S. regulators to resume shipments of two popular models of heart ...

The Food and Drug Administration (FDA) said on Wednesday it is monitoring a potential safety issue involving Boston Scientific Corporation’s (NYSE:BSX) ENDOTAK RELIANCE defibrillation leads, following ...

Boston Scientific Corp. said the company’s Cognis and Teligen defibrillators, surgically implanted devices used to treat abnormal heartbeats, may deliver unneeded shocks to patients, or fail when ...

The problems continue to mount for Boston Scientific Corp.’s (NYSE:BSX) beleaguered defibrillator division, as federal investigators launch probes of the recall of all of its defib products. The U.S.

A Food & Drug Administration panel approved a Boston Scientific Corp. (NYSE:BSX) bid to expand the indication of its cardiac resynchronization therapy defibrillators to cover patients suffering from ...